Appearance is white to off-white crystalline powder, conforming to reference standard. Purity by HPLC is not less than 98.0%, with no single impurity exceeding 1.0%. Moisture content is no more than 1.0%. Loss on drying complies with ≤5.0% specification. Heavy metals (as Pb) are less than 10 ppm. Total protein content is ≥97.0%. The peptide map matches the reference profile, and microbial limits meet pharmaceutical grade requirements.

This compound is a reduced monomeric insulin analog derived from the casiragua (Proechimys guairae), a South American hystricomorph rodent. It serves as a critical research tool in diabetes and metabolic disorder studies.

It is widely used in insulin receptor binding assays and signal transduction research, as it exhibits low self-association (monomeric in solution) and distinct receptor affinity profiles compared to human or porcine insulin. It acts as a key reagent for structure-activity relationship (SAR) studies of insulin analogs, helping to map receptor interaction sites and optimize therapeutic potency.

In pharmaceutical development, it is utilized as a reference standard for evaluating the efficacy of novel insulin formulations, including rapid-acting and long-acting analogs. It also supports diabetes pathophysiology research, particularly in studying insulin resistance and beta-cell function in preclinical models. Additionally, it is employed in biochemical and analytical method validation, such as HPLC and ELISA assays for insulin quantification.